50427-81-1Relevant academic research and scientific papers
Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure–activity relationship and biological activity as potential antitumor and anticonvulsant agents
Lamie, Phoebe F.,El-Kalaawy, Asmaa M.,Abdel Latif, Noha S.,Rashed, Laila A.,Philoppes, John N.
, (2021)
A new series of pyrazolo[3,4-d]pyrimidine/triazine hybrids 6a-r was designed as antitumor and anticonvulsant agents. All the prepared compounds were evaluated against colon (HCT-116), breast (MCF-7) and normal human fibroblast (WI38) cell lines. The most
Synthesis of pyrazolopyrimidinones as sildenafil derivatives and sclerotigenin
Heo, Hoon Gu,Yu, Jin,Jillella, Raveendra,Oh, Chang Ho
supporting information, p. 1678 - 1687 (2018/06/14)
A series of novel pyrazolo pyrimidinone derivatives (3(a–d), 4(a–d), and 6(a–d)) was synthesized from various pyrazolo amides (2a–d) which are synthesized by the reaction between ethyl 5-amino-3-methyl-1-phenyl-1H-pyrazole-4-carboxylate (1) and various lithium amides. In addition, we also described the synthesis of sclerotigenin drug molecule which has quinazoline moiety from simple 2-nitro benzoic acid with high yields.
Synthesis and biological evaluation of novel pyrazolopyrimidines derivatives as anticancer and anti-5-lipoxygenase agents
Rahmouni, Ameur,Souiei, Sawssen,Belkacem, Mohamed Amine,Romdhane, Anis,Bouajila, Jalloul,Ben Jannet, Hichem
, p. 160 - 168 (2016/05/19)
A novel series of 6-Aryl-3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-ones 3a-h were synthesized in a single step via condensation of carboxamide 2 with some aromatic aldehydes (presence of iodine). Treatment of aminopyrazole 1a with acetic anhydri
INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS
-
Page/Page column 45, (2011/11/06)
The present invention is directed to substituted indazole compounds, pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X.
